Clinically Managed Detox

Home
Treatment Programme
Clinically Managed Detox

In This Guide

Heading 2 Example

KEY TAKEAWAYS

Clinically managed residential detoxification is:

A structured detox that uses medication-assisted treatment and regular physical health observations
Takes place in an inpatient rehabilitation unit or hospital
Typically lasts from 7-10 days, but in Abbeycare, it is incorporated into a 28-day rehab programme

When Is Clinical Detox Necessary?

At Abbeycare, we take a personalised approach to detox to ensure withdrawal symptoms and medical needs are cared for before moving on to the rest of the rehab programme.

Physical Addiction

Physical dependence on opioids means a clinical detox in an inpatient environment is necessary because it results in 33% higher rates of abstinence upon discharge compared to outpatient treatment [1].

Severe alcohol withdrawal seizures occur 24-48 hours into detox treatment and require clinical detox in an inpatient rehab so that benzodiazepines are administered [2].

Patients undergoing opioid detox have a standardised mortality ratio of 7.13 for suicide, requiring consistent physical and mental health observations available in clinical detox [3].

Psychological Addiction

Psychological addiction means a clinical detox is necessary because psychological distress during detox amplifies the severity of physical withdrawal symptoms [4].

Anxiety and depression rates are ~10% higher during detox, necessitating intensive therapeutic support and SSRIs available in a clinical setting [5].

Clinical detox typically takes place on an inpatient basis over 7-10 days, allowing patients to avoid environmental triggers that were maintaining substance misuse.

Clinical detox is necessary when substance users fail to stop using alone or on an outpatient basis due to the psychological triggers surrounding the user; continuous medical and pastoral support are therefore required.

Patients with a history of relapse, suicidal ideation or mental health disorders are recommended to undergo a clinical detox because continuous psychological support is available if symptoms worsen.

Malnutrition And Dehydration

Malnutrition means substance abuse treatment is necessary because 60% of patients with substance misuse disorder have co-occurring disordered eating, requiring nutritional support and psychotherapy [6].

Clinical management is necessary because testing conducted in detox identifies vitamin deficiencies and low blood pressure caused by malnutrition.

Clinical detox is required when substance users are malnourished because it offers comprehensive nutritional plans that tailor meals to vitamin deficiencies to supplement physical recovery.

Detoxification treatment provides continuous tracking for symptoms of dehydration caused by substance misuse and allows adequate fluid input and output to be measured in ml as required.

Respiratory Distress

Apnoea occurs in 20% of opioid users and requires a clinical detox so that it is diagnosed and treated using airway management or naloxone in case of overdose [7].

Staff working at a clinical detox centre can make instant referrals to hospital and outpatient respiratory clinics if apnoea is suspected - this is not always possible for at-home detox.

Clinical management of benzodiazepine and opioid addiction uses continuous vital sign tracking, including SPO2 levels - staff alert cases where oxygen levels fall below 95% as this indicates respiratory distress.

Respiratory depression means a clinical detox is necessary as oxygen levels fall to 35.6% from baseline, requiring continuous heart rate tracking and physical observations of skin discolouration [8].

Polysubstance Abuse

Polysubstance abuse means a clinical detox is necessary because 27% of polysubstance users require longer than 21 days to detox [9].

The timeframe for polysubstance detox and subsequent symptoms is often unpredictable, requiring continuous observations of physical health and medication management to prevent contraindications.

25% more polysubstance users drop out of detox compared to mono-substance users, necessitating inpatient detox with regular assessments and medicated symptom management for comfort [10].

8% of users mixing opioids, cannabis, amphetamine, and benzodiazepines do not respond to clonidine, necessitating the switch to a 6-day treatment of buprenorphine in medical detox [11].

Substances such as ketamine require particular care in a polysubstance setting, as combined use with CNS depressants significantly increases the risk of severe withdrawal. See our dedicated ketamine detox programme for more detail.

Delirium Tremens

Delirium tremens (DT) in alcohol cessation occurs in 3-5% of users, necessitating medically managed detox as it results in severe confusion and cardiovascular collapse if left untreated [12].

For those experiencing DT in alcohol withdrawal, the mortality rate is estimated to be 37% without clinical detox but 1-4% with residential care [13].

The onset of DT typically occurs 48-72 hours into abstinence; however, this differs for every patient and requires continuous monitoring throughout the medical detoxification programme.

What To Expect In A Medical Detox

Pre-Admission

First, an initial screening assessment examines patients' medical history, current psychological and physical symptoms, and current and historical substance use.

Patients are advised to seek emergency medical care instead of detox in rehab when presenting with the following symptoms:

Jaundice
Yellowing of the sclera
Ascites (abnormal fluid retention in the abdomen)
Chest pain and laboured breathing
Seizures
Unresponsiveness or unconsciousness
Bloody vomit

Secondly, a psychological evaluation occurs before medical addiction treatment to assess presenting symptoms of depression, anxiety and other co-occurring mental health disorders.

An addiction severity assessment is then carried out to help inform a personalised care plan implemented throughout the 10-day detox and assess whether detox and rehabilitation are required.

Once symptoms are deemed not immediately life-threatening and a diagnosis of addiction has been given, patients wait from 48 hours to 1 week to be admitted to residential detox.

Detox

Medical addiction treatment has the following stages:

Initial detox: Patients stop using all addictive substances upon admission to the detox facility.
Admission and induction: All patients are provided with a personalised care plan outlining individual needs, including medication-assisted treatment if used to replace the substance.
Stabilisation: On days 3-6, patients are stabilised on medication-assisted treatment at the most effective dosage while physical and mental health observations remain ongoing.
Lowered doses: If patients are tapering benzodiazepines due to benzodiazepine addiction, these are reduced gradually throughout detox.
Titration: From days 6-10, doses begin to titrate to 0; however, medications used for symptom management may continue past detox, depending on the severity of presenting symptoms.

Which Substances Require Medical Detox?

Drug	Requires MAT?	Requires Symptom Management?
Alcohol	Yes	Yes
Benzodiazepines	No	Yes
Opioids	Yes	Yes
Barbiturates	No	Yes
Cannabinoids	No	As Necessary
Stimulants	No	Yes
Inhalants	No	Yes
Anabolic Steroids	No	Yes

Drug	Side Effects That Require Medical Supervision During Detox
Alcohol	Delirium Tremens Hallucinations Vomiting
Benzodiazepines	Seizures Rebound panic attacks Psychosis
Opioids	Nausea Respiratory distress
Barbiturates	Rebound anxiety shakes
Cannabinoids	Anxiety Insomnia Irritability
Stimulants	Aggression Agitation Psychosis
Inhalants	Muscle weakness and lack of coordination
Anabolic Steroids	Hormonal imbalances Suicidal ideation Low blood pressure

Medications Used In Detox

Medications Used In Detox	What Substance Detox This Medication Is Used For?	Purpose Of Use In Treatment
Benzodiazepines	Alcohol Benzodiazepines (taper)	Prevents seizures, tremors and delirium tremens Used as a central nervous system depressant
Opioids	Heroin Fentanyl Prescription opioids (e.g., oxycodone)	Lowers withdrawal symptoms Tapering opioid use in a controlled environment
Partial opioid agonists	Heroin Fentanyl Prescription opioids	Craving management
Opioid antagonists	Opioids for relapse prevention	Used when there is a risk of relapse Used in case of overdose
Alpha-2 adrenergic agonists	Opioids (e.g., heroin and prescription opioids) Alcohol Tobacco (rarely)	Induces vasoconstriction to control sweating and high blood pressure
Anticonvulsants	Benzodiazepines Alcohol Barbiturates	Seizure prevention Mood stabilising

Medical Detox Vs Alternatives

Type Of Detox	Medical Supervision?	Medication/ Symptom Management?
Clinically Managed Detox	Yes	Yes
Detox At Home	No	No
Ultra-Rapid Detox	Yes	Yes
Hospital detox	Yes	Yes
Cold turkey	No	No

Type Of Detox	Efficacy (varies by drug type)	Risks
Clinically Managed Detox	75% abstinence over 6 months [14]	Typically carried out in inpatient rehab - no immediate emergency medical care available
Detox At Home	41% abstinence over 60 days [15]	No monitoring of vitals Relapse if triggered at home Overdose if relapse after tolerance has decreased
Ultra-Rapid Detox	55% abstinence over 6 months [16]	Risks of anaesthesia Respiratory distress
Hospital Detox	38% abstinence over 60 days [17]	Limited risks in a controlled environment Not all hospital detoxes have specialised support
Cold Turkey	24% abstinence [18]	High risk of withdrawal symptoms Risk of mortality if quitting alcohol cold turkey

How Do Pre-Existing Conditions Change Medical Detox?

Liver disease changes medical drug detox by limiting the use of Chlordiazepoxide, as case studies indicate it accumulates in the liver of those with hepatic impairment, necessitating the use of lorazepam instead [19].

Those with diabetes require daily glucose monitoring in clinical detox as methadone decreases blood glucose by 68%, causing hypoglycaemia and convulsions [15].

Bradycardia or tachycardia changes medical detox by incorporating more frequent heart rate checks (e.g., up to every 15 minutes).

Bradycardic patients are subject to medication changes as benzodiazepines cause a 5-8% reduction in heart rate [16].

Is Medical Detox Safe?

Clinical treatment safety is managed by daily eyesight observations and monitoring for adverse reactions, enabling medical staff to alter or add medications as required.

The person-centred approach to treatment in a medically managed setting ensures that all psychological needs are met whilst also considering personal health problems, including diabetes and high blood pressure.

At-home detox is deemed to be less safe than medical treatment, as 13.5% relapse at home and require hospital admission [17].

Research suggests that residential detox has a 13% increased rate of programme completion compared to outpatient detox [18].

It is estimated that 90% of home detoxes lead to relapse, resulting in a risk of overdose and health complications when there is no immediate medical supervision, especially when the patient has relapsed alone [19].

All-cause mortality from the effects of substance detox and withdrawal is reduced by up to 90% when cases are medically managed [20].

22% more patients follow through with appropriate aftercare when receiving inpatient medically managed detox than with outpatient treatment [21].

Medical Detox At Abbeycare

Medical treatment at Abbeycare is included in a comprehensive 28-day rehab programme that incorporates medical treatment, symptom management, psychotherapy and extensive aftercare practices.

Unlike home treatment, Abbeycare provides continuous vital sign monitoring up to every 15 minutes to ensure the monitoring of adverse reactions.

Medical treatment at Abbeycare provides care for co-occurring mental health disorders, utilising cognitive behavioural therapy support with a clinical psychologist.

As part of a full rehab programme, patients are given a structured activity timetable for light activities to complete to make withdrawal more comfortable.

As staff are on-site 24/7, any medical concerns regarding withdrawal symptoms or medication are addressed as needed, making the process as comfortable as possible.

References

[1]. Cooper, Richard J. “I Can’t Be an Addict. I Am.” Over-The-Counter Medicine Abuse: A Qualitative Study.’ .” BMJ Open, vol. 3, no. 6, 2013. Accessed 17 July 2025.“I can’t be an addict.", ... I would take eight in one day. But then of course in increasing amounts. Till the point came that I was taking thirty two a day. Even on really bad days, I would take a second lot of thirty two.”
[2]. Substance Abuse and Mental Health Services Administration. Enhancing Motivation for Change in Substance Use Disorder Treatment. Treatment Improvement Protocol (TIP) Series No. 35. 2019. Accessed 17 July 2025.“Appendix B—Screening and Assessment Instruments.”
[3]. Held, Philip, et al. “A Pilot Study of Brief Self-Compassion Training with Individuals in Substance Use Disorder Treatment.” Traumatology, vol. 24, no. 3, Sept. 2018, pp. 219–27. Accessed 17 July 2025.“BSCT is delivered in a group format over the course of four weekly 60-min sessions, ... the duration of mindfulness exercises increases by 5 min each week, beginning with 5 min in the first session.”
[4]. Kimergård, A., et al. “Codeine Use, Dependence and Help-Seeking Behaviour in the UK and Ireland: An Online Cross-Sectional Survey.” QJM: An International Journal of Medicine, vol. 110, no. 9, Apr. 2017, pp. 559–64. Accessed 18 July 2025.“Table 2.”
[5]. Li, Jian‐Neng, et al. “Prefrontal GABA and Glutamate Levels Correlate with Impulsivity and Cognitive Function of Prescription Opioid Addicts: A 1 H‐Magnetic Resonance Spectroscopy Study.” Psychiatry and Clinical Neurosciences, vol. 74, no. 1, Nov. 2019, pp. 77–83. Accessed 18 July 2025.“Table 1.”
[6]. Psarianos, Alexandros E., et al. “Cortisol and β-Endorphin Responses during a Two-Month Exercise Training Program in Patients with an Opioid Use Disorder and on a Substitution Treatment.” International Journal of Molecular Sciences, vol. 26, no. 11, Multidisciplinary Digital Publishing Institute, May 2025, pp. 5178–78. Accessed 18 July 2025.“Table 2.”
[7]. Ware, Orrin D., et al. “Codeine and Promethazine: Exploratory Study on ‘Lean’ or ‘Sizzurp’ Using National Survey Data and an Online Forum.” PLOS ONE, vol. 19, no. 3, Public Library of Science, Mar. 2024. Accessed 18 July 2025.“Table 2.”
[8]. Substance Abuse and Mental Health Services Administration. Counseling Approaches to Promote Recovery from Problematic Substance Use and Related Issues. Treatment Improvement Protocol (TIP) Series 65. 2023. Accessed 18 July 2025.“EXHIBIT 3.11.”
[9]. Peters, Ronald J., et al. “Beliefs and Social Norms about Codeine and Promethazine Hydrochloride Cough Syrup (Cphcs) Onset and Perceived Addiction among Urban Houstonian Adolescents: An Addiction Trend in the City of Lean.” Journal of Drug Education, vol. 33, no. 4, Dec. 2003, pp. 415–25. Accessed 18 July 2025.“Table 1.”
[10]. Carlyle, Molly, et al. “Investigating the Feasibility of Brief Compassion Focused Therapy in Individuals in Treatment for Opioid Use Disorder.” Substance Abuse: Research and Treatment, vol. 13, Jan. 2019. Accessed 18 July 2025.“Table 1.”
[11]. Ware, Orrin D. “Lean/Sizzurp Ingredients, Use, and Coping with Mental Health Symptoms.” Substance Abuse: Research and Treatment, vol. 17, SAGE Publishing, Jan. 2023. Accessed 18 July 2025.“Table 1.”
[12]. Hout, M. C. Van, et al. “‘Codeine Is My Companion’: Misuse and Dependence on Codeine Containing Medicines in Ireland.” Irish Journal of Psychological Medicine, vol. 35, no. 4, Dec. 2018, pp. 275–88. Accessed 18 July 2025."Self-detoxification attempts were common but unsuccessful, and often more excessive in amounts consumed thereafter, ... I tried to cut down on it, gradually cut down, and then I’d just have a bad day and I’d be straight back up to 24 [tablets].”
[13]. Parry, Charles D. H., et al. “Codeine Misuse and Dependence in South Africa: Perspectives of Addiction Treatment Providers.” South African Medical Journal, vol. 107, no. 5, Apr. 2017. Accessed 18 July 2025."Table 4.".
[14]. Doran, Kelly M., et al. “Substance Use and Homelessness among Emergency Department Patients.” Drug and Alcohol Dependence, vol. 188, July 2018, pp. 328–33. Accessed 18 July 2025.“Table 1.”
[15]. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. 2004. Accessed 18 July 2025.“Figure 4-1 – 4-4.”
[16]. MATTOO, S. K., et al. “Abuse of Codeine-Containing Cough Syrups: A Report from India.” Addiction, vol. 92, no. 12, Dec. 1997, pp. 1783–87. Accessed 18 July 2025.“The withdrawal syndrome, reported in 92% patients, usually had an onset between 4-48 hours (4-12 hours in 70% patients) and a duration of 1-5 days (4-5 days in 74% patients). The syndrome was characterized by craving and insomnia (100%); body-aches, lacrimation and rhinorrhoea (98%); anxiety (83%) and loose motions (78%).”
[17]. Barry, Declan T., et al. “An Evaluation of the Feasibility, Acceptability, and Preliminary Efficacy of Cognitive-Behavioral Therapy for Opioid Use Disorder and Chronic Pain.” Drug and Alcohol Dependence, vol. 194, no. 1, Jan. 2019, pp. 460–67. Accessed 21 July 2025.“Table 1.”
[18]. Van Hout, Marie Claire, et al. “Experiences of Codeine Use, Misuse and Dependence: Application of Liese and Franz’s Cognitive Developmental Model of Substance Abuse.” Behavioural and Cognitive Psychotherapy, vol. 45, no. 3, Feb. 2017, pp. 238–52. Accessed 21 July 2025.“The first centred on the misuse of codeine as a coping mechanism to manage and pre-empt the occurrence of physical and psychological distress, in many cases relating to severe trauma and distress, ... ‘Eventually there was not any pain, but I was scared of the pain in my mind’.”
[19]. Luoma, Jason B., et al. “Reducing Self-Stigma in Substance Abuse through Acceptance and Commitment Therapy: Model, Manual Development, and Pilot Outcomes.” Addiction Research & Theory, vol. 16, no. 2, Jan. 2008, pp. 149–65. Accessed 21 July 2025.“Table 2.”
[20]. Walley, Alexander Y., et al. “Association between Mortality Rates and Medication and Residential Treatment after In‐Patient Medically Managed Opioid Withdrawal: A Cohort Analysis.” Addiction, vol. 115, no. 8, Feb. 2020. “Few patients received combined treatment with MOUD and inpatient treatment, but when they did, their risk of all-cause and opioid mortality was reduced by 80–90% compared to no treatment.”
[21]. Day, Ed, and John Strang. “Outpatient versus Inpatient Opioid Detoxification: A Randomized Controlled Trial.” Journal of Substance Abuse Treatment, vol. 40, no. 1, Jan. 2011, pp. 56–66. “The majority (n = 36, 52.9%) of participants returned to an opioid substitution...and 21 (30.9%) attended no follow-up treatment at all in the 6-month follow-up period.” .

About the author

Philippa Scammell

Philippa Scammell MSci holds an integrated Master's degree in Psychology
from the University of York and has completed undergraduate statistical studies at Harvard University. Philippa has substantial experience in inpatient psychiatric care (Foss Park Hospital York), Research in Psychology at University of York, and group therapy facilitation (Kyra Women's Project). Philippa writes on clinical psychology and addiction recovery. Content reviewed by Laura Morris (Clinical Lead).

Share 0

Last Updated March 30, 2026